
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Keynote speakers for ISPE’s 2017 Annual Meeting & Expo include representatives from AstraZeneca and GSK.
On Sep. 21, 2017, the International Society for Pharmaceutical Engineering (ISPE) announced the keynote speakers for its 2017
The ISPE keynote speakers include:
Source:






